HEATHER BLUE: Open Payments
NPI 1306427331 · RICHMOND, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,611 in 139 payments from 14 companies in 2025. Trend: 2023 $1,232 · 2024 $1,284 · 2025 $1,611
Food & beverage: $1,556Education: $55
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 24 | $266 |
| Alkermes, Inc. | 24 | $250 |
| ABBVIE INC. | 32 | $239 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $188 |
| Vanda Pharmaceuticals Inc. | 13 | $185 |
| Neurocrine BioSciences, Inc. | 5 | $104 |
| Teva Pharmaceuticals USA, Inc. | 5 | $100 |
| E.R. Squibb & Sons, L.L.C. | 4 | $74 |
| Janssen Pharmaceuticals, Inc | 3 | $65 |
| Axsome Therapeutics, Inc. | 3 | $55 |
Products named: ARISTADA, VRAYLAR, CAPLYTA, FANAPT, REXULTI, INGREZZA, COBENFY, AUSTEDO XR.
Industry payments across IN — which companies pay providers there.
